Kura Oncology, Inc. – NASDAQ:KURA

Add to watchlist

$7.33

-1.33

-15.46%

Market closed

Open in 2 days

-61.28%

month

-61.28%

quarter

-38.99%

year

Market Cap	686.65M
Enterprise value	772.88M

P/E	-6.07
EV/Sales	N/A
EV/EBITDA	-5.81
Price/Sales	N/A
Price/Book	1.92
PEG ratio	1.99
EPS	-2.17

Revenue	N/A
EBITDA	-178.75M
Income	-168.08M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Kura Oncology Stock Forecast

M Q Y

Last Year

$19

Potential upside: 159.20%

Analysts Price target
Financials & Ratios estimates

Kura Oncology, Inc. (NASDAQ:KURA): Profit margin
Jun 2023	0	-37.17M
Sep 2023	0	-38.60M
Dec 2023	1.27M	-42.78M	-3368.98%
Mar 2024	0	-49.52M

Kura Oncology, Inc. (NASDAQ:KURA): Debt to assets
Jun 2023	494737000	11.16M	2.26%
Sep 2023	473771000	43.83M	9.25%
Dec 2023	448935000	51.66M	11.51%
Mar 2024	553908000	48.82M	8.81%

Kura Oncology, Inc. (NASDAQ:KURA): Cash Flow
Jun 2023	-25.61M	-46.32M	94.00M
Sep 2023	-29.02M	8.55M	84K
Dec 2023	-34.30M	42.19M	691K
Mar 2024	-48.84M	-95.33M	148.36M

Kura Oncology alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Kura Oncology, Inc. (NASDAQ:KURA): Employee count
Aug 2023	131
Sep 2023	133
Oct 2023	133
Nov 2023	133
Dec 2023	131
Jan 2024	131
Feb 2024	131
Mar 2024	142
Apr 2024	142
May 2024	142
Jun 2024	142
Jul 2024	142

Kura Oncology
Hedge Funds Holdings Q1 2022

100.00% +3.47%

of KURA is owned by hedge funds

140 -5

hedge funds hold KURA stock

66.62M +2.57M

shares is hold by hedge funds

KURA hedge funds holdings changes

Kura Oncology, Inc. (NASDAQ:KURA): Insider trades (number of shares)
Period	Buy	Sel
Jan 2024	0	101957
May 2024	0	2615
Nov 2024	0	526

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	18 Nov 2024	FORD KATHLEEN officer: Chief Op..	Common Stock	526	$16.03	$8,434
Sale	20 May 2024	BAIR TERESA BROPHY officer: Chief Legal Officer officer: Chief Legal Officer	Common Stock	2,615	$22.15	$57,917
Sale	30 Jan 2024	DALE STEPHEN officer: Chief Me..	Common Stock	4,825	$21.55	$103,979
Sale	29 Jan 2024	DOYLE THOMAS JAMES officer: SVP, Finance & Accounting officer: SVP, Finance & Account..	Common Stock	594	$17.8	$10,574
Sale	29 Jan 2024	DOYLE THOMAS JAMES officer: SVP, Finance & Accounting officer: SVP, Finance & Account..	Common Stock	761	$17.8	$13,547
Sale	29 Jan 2024	DOYLE THOMAS JAMES officer: SVP, Finance & Accounting officer: SVP, Finance & Account..	Common Stock	963	$17.8	$17,142
Sale	29 Jan 2024	BAIR TERESA BROPHY officer: Chief Legal Officer officer: Chief Legal Officer	Common Stock	2,053	$17.8	$36,545
Sale	29 Jan 2024	FORD KATHLEEN officer: Chief Op..	Common Stock	1,496	$17.8	$26,630
Sale	29 Jan 2024	DALE STEPHEN officer: Chief Me..	Common Stock	4,400	$17.8	$78,324
Sale	29 Jan 2024	DALE STEPHEN officer: Chief Me..	Common Stock	2,758	$17.8	$49,095

Status	Patent	Filling date	Issue date
Application	Application METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS Filling date: 26 Mar 2020 Issue date: 2 Jun 2022	26 Mar 2020	2 Jun 2022
Application	Application METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS Filling date: 12 Mar 2020 Issue date: 12 May 2022	12 Mar 2020	12 May 2022
Application	Application METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS Filling date: 28 Feb 2020 Issue date: 12 May 2022	28 Feb 2020	12 May 2022
Application	Application METHODS OF TREATING SQUAMOUS CELL CARCINOMAS WITH FARNESYLTRANSFERASE INHIBITORS Filling date: 28 Sep 2021 Issue date: 21 Apr 2022	28 Sep 2021	21 Apr 2022
Application	Application THERAPIES FOR SQUAMOUS CELL CARCINOMAS Filling date: 20 Dec 2019 Issue date: 10 Mar 2022	20 Dec 2019	10 Mar 2022
Application	Application METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS Filling date: 31 Oct 2019 Issue date: 6 Jan 2022	31 Oct 2019	6 Jan 2022
Grant	Grant Utility: Methods of treating cancer patients with farnesyltransferase inhibitors Filling date: 13 Jun 2018 Issue date: 28 Dec 2021	13 Jun 2018	28 Dec 2021
Application	Application METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS Filling date: 17 Aug 2021 Issue date: 9 Dec 2021	17 Aug 2021	9 Dec 2021
Grant	Grant Utility: Methods of treating cancer patients with farnesyltransferase inhibitors Filling date: 2 Nov 2017 Issue date: 21 Sep 2021	2 Nov 2017	21 Sep 2021
Application	Application SYNTHESIS OF TIPIFARNIB Filling date: 17 May 2019 Issue date: 12 Aug 2021	17 May 2019	12 Aug 2021

Kura Oncology
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 2 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 27 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 3 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 6 Aug 2023	Q2 2023 Earnings Call Transcript

KURA earnings call transcripts

Kura Oncology
Executives

Insider	Age	Compensation
Dr. Troy Edward Wilson (1969) Chairman, Chief Executive Officer & Pres	56	$1,110,000
Dr. Marc Grasso (1973) Chief Financial Officer & Chief Bus. Officer	52	$715,950
Ms. Kathleen Ford (1947) Chief Operating Officer	78	$683,400
Ms. Kirsten Flowers (1975) Chief Commercial Officer	50	$661,250
Dr. Stephen Dale M.D. (1972) Chief Medical Officer	53	$398,930

Kura Oncology
Latest News

Wednesday, 18 December 2024
13:46	Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)	seekingalpha.com
Monday, 9 December 2024
07:00	Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting	globenewswire.com
Monday, 2 December 2024
07:30	Kura Oncology to Host Virtual Investor Event on December 9, 2024	globenewswire.com
Monday, 25 November 2024
07:30	Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit	globenewswire.com
Wednesday, 20 November 2024
17:52	Kura Oncology to partner with Kyowa Kirin for blood cancer therapy	reuters.com
17:00	Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias	prnewswire.com
17:00	Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias	globenewswire.com
Saturday, 9 November 2024
05:54	Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript	seekingalpha.com
Tuesday, 5 November 2024
09:09	Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting	globenewswire.com
Thursday, 31 October 2024
07:30	Kura Oncology to Report Third Quarter 2024 Financial Results	globenewswire.com
Thursday, 24 October 2024
07:30	Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)	globenewswire.com
Wednesday, 23 October 2024
07:30	Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors	globenewswire.com
Monday, 30 September 2024
18:30	Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology	globenewswire.com
Tuesday, 17 September 2024
07:30	Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors	globenewswire.com
Friday, 9 August 2024
14:07	Kura Oncology, Inc. (KURA) Q2 2024 Earnings Call Transcript	seekingalpha.com
Thursday, 8 August 2024
07:30	Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)	globenewswire.com
Thursday, 1 August 2024
07:30	Kura Oncology to Report Second Quarter 2024 Financial Results	globenewswire.com
Friday, 26 July 2024
07:01	Don't Miss Out: 3 Stocks Poised for a 10X Surge	investorplace.com
Friday, 5 July 2024
07:30	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Monday, 24 June 2024
07:30	Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes	globenewswire.com
Tuesday, 11 June 2024
14:00	Life Science Cares San Diego Teams with Kura Oncology to Support Nutritional Needs of the San Diego Community	businesswire.com
Friday, 7 June 2024
07:30	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Wednesday, 29 May 2024
07:30	Kura Oncology to Participate in Jefferies Global Healthcare Conference	globenewswire.com
Tuesday, 14 May 2024
07:30	Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML	globenewswire.com
Wednesday, 8 May 2024
08:30	2 Incredible Growth Stocks to Buy Hand Over Fist	fool.com
07:30	Kura Oncology to Participate in Bank of America Securities Healthcare Conference	globenewswire.com
Saturday, 4 May 2024
17:28	Kura Oncology, Inc. (KURA) Q1 2024 Earnings Call Transcript	Seeking Alpha
Thursday, 25 April 2024
07:30	Kura Oncology to Report First Quarter 2024 Financial Results	GlobeNewsWire
Thursday, 22 February 2024
07:30	Kura Oncology to Participate in Three Upcoming Investor Conferences	GlobeNewsWire
Tuesday, 20 February 2024
07:30	Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 2 Jul 2025

Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes Well
Seeking Alpha 18 Dec 2024

Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)
Seeking Alpha 12 Dec 2023

Kura Oncology: Riding The Menin Hype Wave In AML Therapy
Seeking Alpha 25 Sep 2023

Kura's Ziftomenib: The Swiss Army Knife In AML Therapy
Seeking Alpha 12 Jul 2023

Kura Oncology: Targeted AML Therapy Continues To Deliver
Seeking Alpha 19 Apr 2023

Kura Oncology: Multiple Catalysts Provide Strong Upside Potential
Seeking Alpha 1 Mar 2023

Syndax Pharmaceuticals: 2023 Is A Pivotal Year
Seeking Alpha 24 Jan 2023

Kura Oncology: Good Cash, Some Good Data, A Few Problems
Seeking Alpha 18 Jul 2022

Kura Oncology: Targeting NPM1 Mutations In Acute Myeloid Leukemia
Seeking Alpha 2 Jun 2022

Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity

Frequently Asked Questions (FAQ)

What's the price of Kura Oncology stock today?

One share of Kura Oncology stock can currently be purchased for approximately $7.33.
When is Kura Oncology's next earnings date?

Unfortunately, Kura Oncology's (KURA) next earnings date is currently unknown.
Does Kura Oncology pay dividends?

No, Kura Oncology does not pay dividends.
How much money does Kura Oncology make?

Kura Oncology has a market capitalization of 686.65M.
What is Kura Oncology's stock symbol?

Kura Oncology, Inc. is traded on the NASDAQ under the ticker symbol "KURA".
What is Kura Oncology's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Kura Oncology?

Shares of Kura Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Kura Oncology's key executives?
Kura Oncology's management team includes the following people:
- Dr. Troy Edward Wilson Chairman, Chief Executive Officer & Pres(age: 56, pay: $1,110,000)
- Dr. Marc Grasso Chief Financial Officer & Chief Bus. Officer(age: 52, pay: $715,950)
- Ms. Kathleen Ford Chief Operating Officer(age: 78, pay: $683,400)
- Ms. Kirsten Flowers Chief Commercial Officer(age: 50, pay: $661,250)
- Dr. Stephen Dale M.D. Chief Medical Officer(age: 53, pay: $398,930)
How many employees does Kura Oncology have?

As Jul 2024, Kura Oncology employs 142 workers.
When Kura Oncology went public?

Kura Oncology, Inc. is publicly traded company for more then 10 years since IPO on 16 Sep 2015.
What is Kura Oncology's official website?

The official website for Kura Oncology is kuraoncology.com.
Where are Kura Oncology's headquarters?

Kura Oncology is headquartered at 12730 High Bluff Drive, San Diego, CA.
How can i contact Kura Oncology?

Kura Oncology's mailing address is 12730 High Bluff Drive, San Diego, CA and company can be reached via phone at 858 500 8800.
What is Kura Oncology stock forecast & price target?

Based on 2 Wall Street analysts` predicted price targets for Kura Oncology in the last 12 months, the avarage price target is $19. The average price target represents a 159.20% change from the last price of $7.33.

Kura Oncology, Inc.

kuraoncology.com

Exchange:

NASDAQ

Full time employees:

142

Industry:

Biotechnology

Sector:

Healthcare

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

858 500 8800

12730 High Bluff Drive
San Diego, CA 92130

CIK: 0001422143
ISIN: US50127T1097
CUSIP: 50127T109